H1 antagonist

H1 antagonists, also called H1 blockers, are a class of medications that block the action of histamine at the H1 receptor, helping to relieve allergic reactions. Agents where the main therapeutic effect is mediated by negative modulation of histamine receptors are termed antihistamines; other agents may have antihistaminergic action but are not true antihistamines.[citation needed]

In common use, the term "antihistamine" refers only to H1-antihistamines. Virtually all H1-antihistamines function as inverse agonists at the histamine H1-receptor, as opposed to neutral antagonists, as was previously believed.

Medical uses

H1-antihistamines are used clinically to treat histamine-mediated allergic conditions. These indications may include:

First-generation H1-antihistamines can act on the central nervous system (CNS). As a result, they are also used for:

H1-antihistamines can be administered topically (through the skin, nose, or eyes) or systemically, based on the nature of the allergic condition.

The authors of the American College of Chest Physicians Updates on Cough Guidelines (2006) recommend that, for cough associated with the common cold, first-generation antihistamine-decongestants are more effective than newer, non-sedating antihistamines. First-generation antihistamines include diphenhydramine (Benadryl), carbinoxamine (Clistin), clemastine (Tavist), chlorpheniramine (Chlor-Trimeton), and brompheniramine (Dimetane). However, a 1955 study of "antihistaminic drugs for colds," carried out by the U.S. Army Medical Corps, reported that "there was no significant difference in the proportion of cures reported by patients receiving oral antihistaminic drugs and those receiving oral placebos. Furthermore, essentially the same proportion of patients reported no benefit from either type of treatment."

Side effects

Adverse drug reactions are most commonly associated with the first-generation H1-antihistamines. This is due to their relative lack of selectivity for the H1-receptor and their ability to cross the blood–brain barrier.

The most common adverse effect is sedation; this "side-effect" is utilized in many OTC sleeping-aid preparations. Other common adverse effects in first-generation H1-antihistamines include dizziness, tinnitus, blurred vision, euphoria, incoordination, anxiety, increased appetite leading to weight gain, insomnia, tremor, nausea and vomiting, constipation, diarrhea, dry mouth, and dry cough. Infrequent adverse effects include urinary retention, palpitations, hypotension, headache, hallucination, psychosis and erectile dysfunction.

The newer, second-generation H1-antihistamines are far more selective for peripheral histamine H1-receptors and have a better tolerability profile compared to the first-generation agents. The most common adverse effects noted for second-generation agents include drowsiness, fatigue, headache, nausea, and dry mouth.

Continuous and/or cumulative use of anticholinergic medications, including first-generation antihistamines, is associated with a higher risk for cognitive decline and dementia in older people.

Pharmacology

Anti-allergy activity

In type I hypersensitivity allergic reactions, an allergen (a type of antigen) interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the allergen cross-links Immunoglobulin E, tyrosine kinases rapidly signal into the cell, leading to cell degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, the histamine can react with local or widespread tissues through histamine receptors.[citation needed]

Histamine, acting on H1-receptors, produces pruritus, vasodilation, hypotension, flushing, headache, bradycardia, bronchoconstriction, increase in vascular permeability and potentiation of pain.

While H1-antihistamines help against these effects, they work only if taken before contact with the allergen. In severe allergies, such as anaphylaxis or angioedema, these effects may be of life-threatening severity. Additional administration of epinephrine, often in the form of an autoinjector, is required by people with such hypersensitivities.

Sedative and hypnotic activity

Comparison of selected sedating and hypnotic antihistamines
Antihistamine Brand name Dosea Time to peak Half-lifeb Metabolism Selective? Anticholinergic?
Cyproheptadine Periactin 4–8 mg 1–3 hours 8–9 hours Unknown No Yes
Diphenhydramine Benadryl 50 mg 2–3 hours 2–9 hours CYP2D6, others No Yes
Doxepin (low-dose) Silenor 3–6 mg 2–3 hours 17 hoursc CYP2D6, others Yes (at low doses) No (at low doses)
Doxylamine Unisom 25 mg 2–3 hours 10–12 hours CYP2D6, others No Yes
Hydroxyzine Atarax, Vistaril 25–100 mg 2 hours 20 hours ADH, CYP3A4, others Yes (at low doses) No
Mirtazapine Remeron 7.5–15 mg 2 hours 20–40 hours CYP2D6, others No No
Quetiapinee Seroquel 25–200 mg 1.5 hours 7 hoursd CYP3A4 No No (at low doses)
Footnotes: a = For sleep/sedation. b = In adults. c Active metabolite nordoxepin half-life is 31 hours. d Active metabolite norquetiapine half-life is 9–12 hours. e Not recommended per literature reviews. Sources: See individual articles for references. See also selected reviews.

Other non-selective sedating antihistamines used as hypnotics include the antihistamines chlorpheniramine and promethazine, the antidepressants amitriptyline, trimipramine, and trazodone, and the antipsychotics olanzapine, risperidone, and chlorpromazine, among others.

First-generation (unselective)

These are the oldest H1-antihistaminergic drugs and are relatively inexpensive and widely available. They are effective in the relief of allergic symptoms, but are typically moderately to highly potent muscarinic acetylcholine receptor (anticholinergic) antagonists as well. These agents also commonly have action at α-adrenergic receptors and/or 5-HT receptors. This lack of receptor selectivity is the basis of the poor tolerability profile of some of these agents, especially when compared with the second-generation H1-antihistamines. Patient response and occurrence of adverse drug reactions vary greatly between classes and between agents within classes.

Classes

The first H1-antihistamine discovered was piperoxan, by Ernest Fourneau and Daniel Bovet (1933) in their efforts to develop a guinea pig animal model for anaphylaxis at the Pasteur Institute in Paris. Bovet went on to win the 1957 Nobel Prize in Physiology or Medicine for his contribution. Following their discovery, the first-generation H1-antihistamines were developed in the following decades. They can be classified on the basis of chemical structure, and agents within these groups have similar properties. For details about chemical structure, see § Chemical structure below.

ClassDescriptionExamples
EthylenediaminesEthylenediamines were the first group of clinically effective H1-antihistamines developed.
EthanolaminesDiphenhydramine was the prototypical agent in this group. Significant anticholinergic adverse effects, as well as sedation, are observed in this group, but the incidence of gastrointestinal adverse effects is relatively low.
AlkylaminesThe isomerism is a significant factor in the activity of the agents in this group. E-triprolidine, for example, is 1000-fold more potent than Z-triprolidine. This difference relates to the positioning and fit of the molecules in the histamine H1-receptor binding site. Alkylamines are considered to have relatively fewer sedative and gastrointestinal adverse effects, but relatively greater incidence of paradoxical central nervous system (CNS) stimulation.
PiperazinesThese compounds are structurally related to the ethylenediamines and the ethanolamines, and produce significant anticholinergic adverse effects with the exception of hydroxyzine, which has low to no affinity for muscarinic acetylcholine receptors and therefore produces negligible anticholinergic side-effects. Compounds from this group are often used for motion sickness, vertigo, nausea, and vomiting. The second-generation H1-antihistamine cetirizine also belongs to this chemical group.
Tricyclics and TetracyclicsThese compounds differ from the phenothiazine antipsychotics in the ring-substitution and chain characteristics. They are also structurally related to the tricyclic antidepressants (and tetracyclics), explaining the H1-antihistaminergic adverse effects of those three drug classes and also the poor tolerability profile of tricyclic H1-antihistamines. The second-generation H1-antihistamine loratadine was derived from compounds in this group.

Second-generation

Second-generation H1-antihistamines are newer drugs that are much more selective for peripheral H1 receptors as opposed to the central nervous system H1 receptors and cholinergic receptors. This selectivity significantly reduces the occurrence of adverse drug reactions, such as sedation, while still providing effective relief of allergic conditions. Most of these compounds have peripheral selectivity because they are zwitterionic at physiological pH (around pH 7.4). As such, they are very polar, meaning they are less likely to cross the blood–brain barrier and act mainly outside the central nervous system.

Examples of systemic second-generation antihistamines include:

Examples of topical second-generation antihistamines include:

Chemical structure

H1-antihistamines

H1-antihistamines are mainly used to treat allergy or other types of inflammatory processes related to IgE production. Most drugs from this class act as histamine inverse agonists rather than neutral antagonists, which means they decrease the constitutive activity of the histamine receptor below its basal level.

This activity is closely related to the general chemical structure of H1-antihistamines.:

  • One aromatic group (such as a phenyl, substituted phenyl, thienyl, or pyridyl), that mimics hitamine's imidazole group;
  • A second aromatic group, which provides extra affinity to the receptor;
  • A spacer, which is usually a short chain of two or three carbons;
  • An end amine group, typically a tertiary aliphatic amine with simple alkyl substituents, that mimics hitamine's end amine group.
General structure of H1-antihistamines.

From there, you can classify almost any first-generation H1-antihistamine.:

Structural Classification of H1-Antihistamines.
Generation Chemical Class X group Spacer R1 R2 Examples
1st-generation antihistamines Ethylenediamines N -(CH2)n- CH3 CH3
Phenbenzamine.
Methapyrilene
Ethanolamine ethers CHO -(CH2)n- CH3 CH3
Clemastine
Diphenhydramine
Alkyl amines CH or C=C -(CH2)n- CH3 CH3
Pheniramine
Chlorphenamine
Piperazines CH Incorporated into a piperazine ring Alkyl or aralkyl group
Hydroxyzine
Cyclizine
Tricyclics N or C=C Branched 2–3 carbon chain CH3 CH3
Cyproheptadine
Promethazine
2nd-generation antihistamines Various Various Various Various Various
Fexofenadine, a 2nd generation antihistamine.

Regulation

Over-the-counter

H1 receptor antagonists that are approved for over-the-counter sale in the United States include the following.

First-generation

Common/marketed:

Uncommon/discontinued:

Second-generation

See also